Cagrilintide

What is Cagrilintide?

Cagrilintide is a long-acting acylated amylin analogue designed for once-weekly dosing. It is being developed by Novo Nordisk both as a standalone treatment and in combination with semaglutide (CagriSema). The combination has shown weight loss of up to 22.7% in Phase III trials, potentially matching or exceeding tirzepatide.

What Cagrilintide Is Investigated For

Cagrilintide is a long-acting amylin analogue investigated for weight management, developed by Novo Nordisk almost exclusively as the combination partner for semaglutide in CagriSema rather than as a standalone therapy. The strongest evidence comes from the Phase 3 REDEFINE program (REDEFINE 1 in obesity without diabetes, REDEFINE 2 in obesity with type 2 diabetes), which reported approximately 20-23% mean weight reduction with CagriSema versus ~15% with semaglutide alone — a genuinely meaningful gain that positions the combination as a direct competitor to tirzepatide. Phase 2 monotherapy data showed ~10% body weight reduction at the 2.4 mg weekly dose. Neither cagrilintide nor CagriSema is FDA-approved as of early 2026; Novo has indicated regulatory filings are planned, and monotherapy cagrilintide is not part of the near-term regulatory pathway. The main honest caveats are the absence of dedicated cardiovascular outcomes data and generally higher GI tolerability costs than semaglutide alone, reflecting the dual-pathway pharmacology.

History & Discovery

Cagrilintide is the product of Novo Nordisk's long arc of work on amylin, the pancreatic beta-cell co-secreted hormone that contributes to postprandial satiety and glucose regulation. That program produced pramlintide (Symlin) — a short-acting amylin analog approved by the FDA in 2005 as an adjunct to insulin for type 1 and type 2 diabetes. Pramlintide demonstrated the clinical viability of amylin agonism but has seen modest real-world uptake because of its requirement for multiple daily injections and its narrow labeled indication. Cagrilintide (internal designation AM833, clinical designation NN9838) was developed specifically to address the dosing-frequency limitation: it is an acylated amylin analog engineered to bind albumin and enable once-weekly subcutaneous administration. Early-phase work published in the late 2010s and early 2020s established its pharmacokinetics, safety, and monotherapy weight-loss signal, with a 2021 Phase 2 dose-finding trial showing ~10% body weight reduction at the 2.4 mg weekly dose over 26 weeks in people with overweight or obesity. The program's strategic pivot — and the source of most current attention — is the fixed-dose combination with semaglutide, known as CagriSema. The REDEFINE trial program, including REDEFINE 1 (obesity without diabetes) and REDEFINE 2 (obesity with type 2 diabetes), reported Phase 3 results in 2024–2025 showing mean weight reductions around 20–23% with CagriSema versus ~15% with semaglutide alone, positioning the combination as a potential direct competitor to tirzepatide and next-generation incretin polypharmacy. The 2026 REDEFINE 5 readout in Japan and Taiwan reinforced the pattern in an East Asian population (−18.4% versus −11.9% with semaglutide alone at 68 weeks), addressing one of the regional-generalizability questions raised against the original REDEFINE 1 cohort. Novo Nordisk has not sought approval of cagrilintide as monotherapy; the combination has been the regulatory focus.

How It Works

Cagrilintide mimics amylin, a natural hormone that makes you feel full after eating. Combined with semaglutide (which mimics GLP-1), the two hormones work through different brain pathways to provide stronger appetite suppression than either alone.

Cagrilintide activates amylin receptors (AMY1 and AMY3, composed of calcitonin receptor + RAMP1 or RAMP3) in the area postrema and nucleus tractus solitarius. This promotes satiety, slows gastric emptying, and suppresses glucagon. The acylation with a C18 fatty diacid enables albumin binding for weekly dosing. When combined with semaglutide's GLP-1R agonism, the dual pathway activation produces complementary and potentially synergistic appetite suppression through distinct hypothalamic and brainstem circuits.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Cagrilintide:

• 01Cardiovascular outcomes — no dedicated CVOT for cagrilintide or CagriSema has reported; cardiovascular and mortality endpoint data will be critical for positioning against semaglutide (which has SELECT data) and tirzepatide (which has ongoing SURPASS-CVOT).
• 02Long-term safety beyond 2 years — Phase 3 trials run ~68–72 weeks; data on 3–5+ year continuous use is not yet available.
• 03Discontinuation trajectory — specific weight-regain and metabolic-regain data after stopping CagriSema, versus stopping semaglutide alone, would inform real-world maintenance strategy.
• 04Responder vs. non-responder biology — a substantial minority of participants in all GLP-1/amylin obesity trials do not achieve clinically meaningful weight loss; predictors of response remain poorly characterized.
• 05Monotherapy value of cagrilintide — Novo is focusing on combination development, but whether cagrilintide alone would be a distinctive option for specific subgroups (e.g., GLP-1 non-responders) is not being pursued regulatorily.
• 06Head-to-head vs. tirzepatide — the most clinically relevant comparison is to the existing dual-agonist standard; direct head-to-head trials are limited and the field is relying on cross-trial comparisons.

Forms & Administration

Weekly SC injection. CagriSema: cagrilintide 2.4mg + semaglutide 2.4mg in single injection. Dose titration over several weeks. All injectable peptides should only be administered under the guidance of a qualified healthcare provider. Never self-administer without clinician oversight.

Dosing & Protocols

The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.

Cagrilintide and CagriSema are investigational and not FDA-approved as of this writing. Any clinical use outside a registered trial is through compounding, research-chemical channels, or regulatory pathways that sit well outside the standard of care — and compounded amylin analogs lack the quality assurance of the approved sponsor's product. This profile describes trial-program data, not a prescribing recommendation.

Timeline of Effects

Common Questions

Who Cagrilintide Is NOT For

Drug & Supplement Interactions

Cagrilintide slows gastric emptying, which can delay absorption of orally administered drugs — particularly those with narrow absorption windows or time-sensitive pharmacokinetics (oral contraceptives, certain antibiotics, thyroid hormone). The clinical magnitude is generally manageable but worth considering for individual medications. Insulin and sulfonylureas: in patients with type 2 diabetes, combining cagrilintide-containing regimens with insulin or insulin secretagogues increases hypoglycemia risk. Dose reduction of the diabetes regimen is typically warranted as CagriSema titrates up. Other GLP-1 agonists: concurrent use with semaglutide, liraglutide, tirzepatide, or other incretin-class agents alongside CagriSema is not studied and would be redundant or hazardous given overlapping mechanisms. Anti-emetics: routine co-administration is not required but may be used in the titration phase for individuals struggling with nausea. Beyond these class-level considerations, cagrilintide's pharmacokinetic interactions are not extensively characterized in the published literature; albumin binding makes protein-binding drug interactions a theoretical consideration rather than a documented clinical problem.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions